PLK1 and neoplasm: Metadata analysis of publicly available genomic data from TCGA (The Cancer Genome Atlas Program) dataset on 33 different cancer types patients who were treated with PLK1 inhibitor demonstrated increased anti-tumor immunity characterized by an upregulated expression of NK (natural killer)-cell-like gene signatures and genes involved in antigen presentation such as Transporter associated with antigen processing 1 & 2 (TAP1 and TAP2) [90].